FDA warns research-use-only peptide sellers

The Food and Drug Administration issued a fresh round of warning letters on August 24, 2026, to five companies that sell peptide products online: Royal Peptides LLC, NuScience Peptides LLC, Peak Performance Peptides, TXP Innovations LLC (doing business as Tex Peptides), and Peptide Partners LLC ^[1]. Each letter cites the same two problems: unapproved new drugs and misbranding ^[1]. The letters were posted to FDA's public warning letter database on September 1, 2026 ^[1].

This batch fits a pattern the agency has been flagging for months. FDA has said it has warned companies that sell unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide while falsely labeling them "for research purposes" or "not for human consumption" ^[2]. The agency says these products are often sold directly to consumers with dosing instructions attached, despite the research-only label, and that their quality is unknown ^[2]. FDA has also separately warned telehealth companies for marketing unapproved drugs such as retatrutide, active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 substances to compounders, and outsourcing facilities for repackaging retatrutide ^[2]. Retatrutide and cagrilintide cannot legally be used in compounding at all, since they are not components of any FDA-approved drug and have not been found safe and effective for any condition, according to the agency ^[2].

The five newest letters were all issued by FDA's Center for Drug Evaluation and Research and logged under the same subject heading, "Unapproved New Drugs/Misbranded," in the agency's public tracker, which lists thousands of warning letters across all FDA-regulated products ^[1]. The database does not include the text of these particular letters in the material reviewed here, so the specific claims or ingredients FDA objected to at each company are not yet known from public sources.

Why it matters for patients

Peptide products sold as "research use only" are not reviewed by FDA for safety, effectiveness, or quality before they reach the market, whether they are labeled for research or for human use ^[2]. FDA has said these unapproved GLP-1-type products carry real risks: they could contain the wrong ingredient, too much or too little active ingredient, or no active ingredient at all ^[2]. The agency has already logged adverse events tied to compounded and unapproved GLP-1 drugs. As of May 31, 2026, FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, though it says these figures likely undercount actual harm because many pharmacies are not required to report ^[2]. FDA has separately confirmed counterfeit Ozempic has entered the U.S. drug supply ^[2].

FDA recommends consumers watch for red flags from any online seller, including deep discounts, no requirement for a doctor's screening, no licensed doctor available to answer questions, spelling errors on labels, or packaging that arrives damaged, warm, or without proper refrigeration for injectable products ^[2]. The agency also warns that some products use salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients than those used in FDA-approved drugs and have unknown chemical and pharmacologic properties ^[2].

What happens next

FDA's warning letter database shows the five August 24, 2026, letters as posted without response or closeout letters yet on file ^[1]. Under FDA's standard process, companies that receive such letters are expected to respond and correct the violations, and the agency's public tracker will be updated if and when responses or closeout letters are added ^[1]. It is not yet known from available sources whether any of the five companies have stopped sales, changed labeling, or otherwise responded to the letters.